• Je něco špatně v tomto záznamu ?

Development of minimum standards of care for juvenile localized scleroderma

T. Constantin, I. Foeldvari, CE. Pain, A. Pálinkás, P. Höger, M. Moll, D. Nemkova, L. Weibel, M. Laczkovszki, P. Clements, KS. Torok,

. 2018 ; 177 (7) : 961-977. [pub] 20180504

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033104
E-zdroje Online Plný text

NLK ProQuest Central od 1996-01-01 do Před 1 rokem
CINAHL Plus with Full Text (EBSCOhost) od 2012-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 1997-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1996-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1996-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 1996-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1996-01-01 do Před 1 rokem

Odkazy

PubMed 29728839
DOI 10.1007/s00431-018-3144-8
Knihovny.cz E-zdroje

Juvenile localized scleroderma (jLS), also known as morphea, is an orphan disease. Pediatric guidelines regarding diagnosis, assessment, and management are lacking.Our objective was to develop minimum standards of care for diagnosis, assessment, and management of jLS. A systematic review was undertaken to establish the pediatric evidence for assessment and monitoring of jLS. An expert panel, including members of the Pediatric Rheumatology European Society (PRES) Scleroderma Working Group, were invited to a consensus meeting where recommendations were developed based on evidence graded by the systematic review and, where evidence was lacking, consensus opinion. A nominal technique was used where 75% consensus was taken as agreement. Recommendations for diagnosis, assessment, and management were developed. Due to a lack of pediatric evidence, these were primarily consensus driven. Careful assessment for extra-cutaneous manifestations including synovitis, brain involvement, and uveitis were key features together with joint assessments between Dermatology and Rheumatology to improve and standardize care. CONCLUSION: Management of jLS is varied. These recommendations should help provide standardization of assessment and care for those with this rare and potentially debilitating condition. What is Known: • Children with juvenile localized scleroderma (jLS) are managed by a number of specialties including pediatric rheumatologists and dermatologists, sometimes in shared clinics. Studies have shown that management varies considerably and that there are notable differences between specialties [1]. • There is very little published guidance on management of jLS. What is new: • These recommendations aim to standardize diagnosis, assessment, and management through review of pediatric evidence and consensus agreement. • Joint review of patients by both pediatric rheumatologists and dermatologists is recommended.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033104
003      
CZ-PrNML
005      
20181024152814.0
007      
ta
008      
181008s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00431-018-3144-8 $2 doi
035    __
$a (PubMed)29728839
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Constantin, Tamás $u Semmelweis University, Budapest, Hungary. tamas.constantin@gmail.com.
245    10
$a Development of minimum standards of care for juvenile localized scleroderma / $c T. Constantin, I. Foeldvari, CE. Pain, A. Pálinkás, P. Höger, M. Moll, D. Nemkova, L. Weibel, M. Laczkovszki, P. Clements, KS. Torok,
520    9_
$a Juvenile localized scleroderma (jLS), also known as morphea, is an orphan disease. Pediatric guidelines regarding diagnosis, assessment, and management are lacking.Our objective was to develop minimum standards of care for diagnosis, assessment, and management of jLS. A systematic review was undertaken to establish the pediatric evidence for assessment and monitoring of jLS. An expert panel, including members of the Pediatric Rheumatology European Society (PRES) Scleroderma Working Group, were invited to a consensus meeting where recommendations were developed based on evidence graded by the systematic review and, where evidence was lacking, consensus opinion. A nominal technique was used where 75% consensus was taken as agreement. Recommendations for diagnosis, assessment, and management were developed. Due to a lack of pediatric evidence, these were primarily consensus driven. Careful assessment for extra-cutaneous manifestations including synovitis, brain involvement, and uveitis were key features together with joint assessments between Dermatology and Rheumatology to improve and standardize care. CONCLUSION: Management of jLS is varied. These recommendations should help provide standardization of assessment and care for those with this rare and potentially debilitating condition. What is Known: • Children with juvenile localized scleroderma (jLS) are managed by a number of specialties including pediatric rheumatologists and dermatologists, sometimes in shared clinics. Studies have shown that management varies considerably and that there are notable differences between specialties [1]. • There is very little published guidance on management of jLS. What is new: • These recommendations aim to standardize diagnosis, assessment, and management through review of pediatric evidence and consensus agreement. • Joint review of patients by both pediatric rheumatologists and dermatologists is recommended.
650    _2
$a dítě $7 D002648
650    _2
$a konsensus $7 D032921
650    _2
$a lidé $7 D006801
650    _2
$a plošný screening $x metody $7 D008403
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a kvalita života $7 D011788
650    _2
$a lokalizovaná sklerodermie $x diagnóza $x terapie $7 D012594
650    12
$a standardní péče $7 D059039
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Foeldvari, Ivan $u Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany.
700    1_
$a Pain, Clare E $u Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
700    1_
$a Pálinkás, Annamária $u Semmelweis University, Budapest, Hungary.
700    1_
$a Höger, Peter $u Department of Paediatric Dermatology, Catholic Children's Hospital Wilhelmstift, Hamburg, Germany.
700    1_
$a Moll, Monika $u University Childrens Hospital, Tuebingen, Germany.
700    1_
$a Nemkova, Dana $u Charles University, Prague, Czech Republic.
700    1_
$a Weibel, Lisa $u Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland.
700    1_
$a Laczkovszki, Melinda $u Semmelweis University, Budapest, Hungary.
700    1_
$a Clements, Philip $u David Geffen School of Medicine at UCLA, Division of Rheumatology, Los Angeles, CA, USA.
700    1_
$a Torok, Kathryn S $u University of Pittsburgh, Pittsburgh, PA, USA.
773    0_
$w MED00009638 $t European journal of pediatrics $x 1432-1076 $g Roč. 177, č. 7 (2018), s. 961-977
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29728839 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181024153323 $b ABA008
999    __
$a ok $b bmc $g 1340018 $s 1030098
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 177 $c 7 $d 961-977 $e 20180504 $i 1432-1076 $m European journal of pediatrics $n Eur J Pediatr $x MED00009638
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace